“Finding a safe and effective vaccine against the SARS-CoV-2 virus is one of the most pressing scientific challenges of our time. Lachlan Mackinnon, Oxford Sciences Innovation Principal and SpyBiotech Chairman, added: SIIPL is looking forward to working alongside SpyBiotech to advance this candidate through clinical development.” This new technology has the potential to be a powerful new approach to tackling the pandemic. “We are very excited about the collaboration with SpyBiotech to work on this novel vaccine for COVID-19.
![serum institute of india serum institute of india](https://accesstovaccinesindex.org/media/atvi/Company-scores-SerumInstitute-ATVI-170303.png)
Our technology can be combined with multiple vaccine delivery platforms to create a plug and display vaccine which is critical for generating vaccines rapidly and safely.”Īdar Poonawalla, Chief Executive Officer of SIIPL, added: “For SpyBiotech, this is an opportunity to provide an accelerated proof point for our platform technology, alongside the other candidates which we are advancing into clinical development.
![serum institute of india serum institute of india](https://cdn.dnaindia.com/sites/default/files/styles/full/public/2018/02/14/651412-indian-army-pti.jpg)
“Combining SpyBiotech’s unique platform technology with Serum’s extensive expertise developing VLPs and its manufacturing capability is an exciting development at a critical time, giving us the tools to produce the large volume of doses required to support the global fight against COVID-19.
#Serum institute of india trial
“We are delighted to have dosed the first subjects in this trial with Serum Institute of India, the world’s largest vaccine manufacturer by number of doses produced and to be advancing this COVID-19 vaccine candidate into clinical trials. Professor Sumi Biswas, Chief Executive Officer and co-Founder of SpyBiotech, commented: SpyBiotech has exclusive rights from the University of Oxford to apply, commercialise and sub-license the “plug and display” technology for vaccine development. The technology can be used for an exceptionally broad range of applications in vaccine development and has established proof of concept data in a viral, bacterial, parasitic diseases and chronic diseases and cancer.
![serum institute of india serum institute of india](https://images.livemint.com/img/2021/05/04/1600x900/4ab46b94-a9d3-11eb-af25-752eabb3bc71_1620089250859_1620089275176.jpg)
Sp圜atcher/SpyTag is a platform technology which allows antigens to be displayed onto VLPs with a covalent, irreversible bond in a highly stable and effective way with specific orientation/epitope presentation and high density. The coronavirus spike protein’s receptor-binding domain is displayed on the VLP, taking advantage of the platform’s properties to induce a potent immune response.
![serum institute of india serum institute of india](https://1.bp.blogspot.com/-IFYCHXQOfpA/XqpWvpo_RnI/AAAAAAABfOo/1pUccMlDWJwBTaMFOOArmkIyqq-zMAl4QCLcBGAsYHQ/w1200-h630-p-k-no-nu/Serum-Institute-of-India-Pvt-Ltd.jpg)
HBsAg VLPs are a licensed vaccine with excellent safety and immunogenicity data in humans and which are currently manufactured to billions of doses. The vaccine candidate uses SpyBiotech’s proprietary Sp圜atcher/SpyTag protein “superglue” technology to display the coronavirus spike protein on the surface of Hepatitis B surface antigen (HBsAg) VLPs. The Phase I/II study has been initiated in Australia. Financial terms of the agreement are not being disclosed. SpyBiotech has signed an exclusive global licensing agreement with SIIPL for the development of a novel virus-like-particle (VLP) vaccine targeting COVID-19. Oxford, UK, September 8: SpyBiotech, a company with a novel vaccine platform to target infectious diseases, cancer and chronic diseases, today announces that its partner the Serum Institute of India (SIIPL) has dosed the first subjects in a Phase I/II trial of a novel virus-like particle (VLP) vaccine targeting COVID-19. SpyBiotech and Serum Institute of India announce that the first subjects have been dosed in a Phase I/II trial of a novel virus-like particle vaccine targeting COVID-19